CTLA4 and congenital rubella syndrome: Importantly, no grade 3/4 CRS, immune effector-cell neurotoxicity, or treatment-related deaths were reported with tebentafusp, underscoring its predominantly manageable, mechanism-based safety profile relative to the broader autoimmune toxicities of combined CTLA-4/PD-1 inhibition.